| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 04/05/2001 | WO2001023546A1 37 human secreted proteins |
| 04/05/2001 | WO2001023402A1 43 human secreted proteins |
| 04/05/2001 | WO2001023389A2 Certain alkylene diamine-substituted heterocycles |
| 04/05/2001 | WO2001023388A2 AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
| 04/05/2001 | WO2001023382A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 04/05/2001 | WO2001023376A1 Isonipecotamides for the treatment of integrin-mediated disorders |
| 04/05/2001 | WO2001023365A1 Quinazolinones |
| 04/05/2001 | WO2001023359A1 Aryl-sulfonamide substituted benzimidazol derivatives and use of said as tryptase inhibitors |
| 04/05/2001 | WO2001023357A2 Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists |
| 04/05/2001 | WO2001023000A1 Coating preparations soluble in lower digestive tract |
| 04/05/2001 | WO2001022987A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 04/05/2001 | WO2001022969A2 Vasopressin agonist formulation and process |
| 04/05/2001 | WO2001022945A1 Vasopressin antagonist formulation and process |
| 04/05/2001 | WO2001012602A8 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands |
| 04/05/2001 | WO2001006015A8 NOVEL GLYCOSYL SULFOTRANSFERASES GST-4α, GST-4β, AND GST-6 |
| 04/05/2001 | WO2001002397A9 Tricyclic compounds having spiro union |
| 04/05/2001 | WO2000073450A3 Cytoskeleton-associated proteins |
| 04/05/2001 | WO2000056891A3 Human transmembrane proteins |
| 04/05/2001 | WO2000055343A3 Retrovirus producting cells utilizing a high multiplicity of transduction |
| 04/05/2001 | WO2000040228A3 Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
| 04/05/2001 | WO2000030668A9 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration |
| 04/05/2001 | WO1999060126A9 Protein z-dependent protease inhibitor |
| 04/05/2001 | US20010000179 Inhibitors of typsin-like serine protease; anticoagulants |
| 04/05/2001 | US20010000143 Using dimethyl ether and elevated temperature/pressure to dissolve the solid; releasing the pressure to precipitate the fine powder and expand the ether into a gas; drugs; vitamins; carotenoid, especially beta-carotene; foods; cosmetics |
| 04/05/2001 | DE19947010A1 Das Gen PRV-1 und dessen Verwendung The PRV-1 gene and its use |
| 04/05/2001 | CA2388474A1 Vasopressin antagonist formulation and process |
| 04/05/2001 | CA2387702A1 The prv-1 gene and use thereof |
| 04/05/2001 | CA2386002A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 04/05/2001 | CA2385971A1 Vasopressin agonist formulation and process |
| 04/05/2001 | CA2385921A1 Quinazolinones |
| 04/05/2001 | CA2385169A1 43 human secreted proteins |
| 04/05/2001 | CA2385001A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 04/05/2001 | CA2384662A1 41 human secreted proteins |
| 04/05/2001 | CA2384659A1 37 human secreted proteins |
| 04/05/2001 | CA2382892A1 Substituted benzimidazol derivatives, processes for preparing them and their use as pharmaceutical compositions |
| 04/05/2001 | CA2352957A1 Isonipecotamides for the treatment of integrin-mediated disorders |
| 04/04/2001 | EP1088822A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 04/04/2001 | EP1087992A1 Antithrombotic compounds |
| 04/04/2001 | EP1087976A1 Polymorphic clopidogrel hydrogenesulphate form |
| 04/04/2001 | EP1087937A1 Cyclic hydroxamic acids as metalloproteinase inhibitors |
| 04/04/2001 | EP0939767A4 Modified factor viii |
| 04/04/2001 | EP0824515B1 Substituted phenyl amidines, medicaments containing these compounds and process for producing them |
| 04/04/2001 | EP0756638B1 Means for treating disorders in the blood coagulation cascade |
| 04/04/2001 | EP0620732B1 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| 04/04/2001 | CN1290265A Thrombin receptor antagonists |
| 04/04/2001 | CN1290260A Hydroxamic and carboxylic acid derivatives |
| 04/04/2001 | CN1290180A Sterile complex of therapeutic peptide bond to polysaccharide |
| 04/04/2001 | CN1290179A Bipapcitide-based pharmaceutical compositions for imaging and treating thrombi |
| 04/04/2001 | CN1290170A Peritoneal dialysis solution containing modified icodextrins |
| 04/04/2001 | CN1290165A Benzothiazole Protein tyrosine kinase inhibitors |
| 04/03/2001 | US6211344 Purifying the starting plasma by immunoadsorption with monoclonal and polyclonal antibodies against factor v to prepare factor v-deficient plasma capable of detecting inactivatable factor v from starting plasma using antibodies |
| 04/03/2001 | US6211210 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use |
| 04/03/2001 | US6211208 2-aminopyridines containing fused ring substituents |
| 04/03/2001 | US6211200 Administering zinc chelated imidazo(4,5-d)imidazole compounds as granulocyte colony stimulating factor agonists |
| 04/03/2001 | US6211183 Selective factor Xa inhibitors |
| 04/03/2001 | US6210913 Modulation of integrin-mediated signal transduction |
| 03/29/2001 | WO2001021812A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | WO2001021662A1 Signal sequences for the production of leu-hirudine via secretion by e. coli in a culture medium |
| 03/29/2001 | WO2001021658A1 32 human secreted proteins |
| 03/29/2001 | WO2001021628A1 A substantially cell membrane impermeable compound and use thereof |
| 03/29/2001 | WO2001021582A1 Biphenyl derivatives used as nhe-3 inhibitors |
| 03/29/2001 | WO2001021259A2 Use and compositions for treating platelet-related disorders using anagrelide |
| 03/29/2001 | WO2001021205A1 Coupling factor 6 inhibitor and potentiator and use thereof |
| 03/29/2001 | WO2001021204A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | WO2001021185A1 Novel pharmacological activities of curcuma longa extracts |
| 03/29/2001 | WO2001021180A1 Thrombopoietin mimetics |
| 03/29/2001 | WO2001021163A2 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 03/29/2001 | WO2000037487A8 αvβ6 INTEGRIN INHIBITORS |
| 03/29/2001 | WO2000012741A9 Inducible expression system |
| 03/29/2001 | US20010000075 Neurotactin and uses therefor |
| 03/29/2001 | DE19945810A1 Substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Substituted benzimidazole derivatives, processes for their preparation and their use as medicaments |
| 03/29/2001 | DE19945302A1 Biphenylderivate als NHE-3-Inhibitoren Biphenyl as NHE-3 inhibitors |
| 03/29/2001 | DE19944870A1 Signalsequenzen zur Herstellung von Leu-Hirudin über Sekretion durch E. coli in das Kulturmedium Signal sequences for preparing Leu-hirudin by E. coli via secretion into the culture medium |
| 03/29/2001 | CA2387529A1 Biphenyl derivatives as nhe-3 inhibitors |
| 03/29/2001 | CA2385552A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | CA2385480A1 32 human secreted proteins |
| 03/29/2001 | CA2383598A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | CA2382547A1 Methods and compositions for treating platelet-related disosders |
| 03/29/2001 | CA2351482A1 Novel pharmacological activities of curcuma longa extracts |
| 03/29/2001 | CA2350700A1 Coupling factor 6 inhibitor and potentiator and use thereof |
| 03/28/2001 | EP1087011A2 Methods for preventing degradation of protein c |
| 03/28/2001 | EP1086700A2 A solid pharmaceutical composition for dialysate containing sodium bicarbonate and a process for producing the same |
| 03/28/2001 | EP1086122A1 Pyrazinone protease inhibitors |
| 03/28/2001 | EP1086099A1 Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
| 03/28/2001 | EP1086086A1 Imidazolyl derivatives and their use as somatostatin receptor ligands |
| 03/28/2001 | EP1086085A1 INHIBITORS OF p38 |
| 03/28/2001 | EP1085900A1 Use of erythropoietin for the treatment of haemochromatoses |
| 03/28/2001 | EP1085871A1 QUINAZOLINONE INHIBITORS OF cGMP PHOSPHODIESTERASE |
| 03/28/2001 | CN1289341A Thrombin inhibitors |
| 03/28/2001 | CN1289322A Hydroxamic and carboxylic acid derivatives |
| 03/28/2001 | CN1288732A Soft concentrated fish oil capsule and its supercritical CO2 extraction and rectification process |
| 03/28/2001 | CN1063796C Preparation method for drythropoietin isoforms |
| 03/27/2001 | US6207803 Amino acid sequence of polypeptide; anticarcinogenic agents; antitumor agents; treatment of automimmune disorders, blood disorders; alzheimer's/parkinson's disease, septic shock, osteoporosis, polycystic kidney disease; viricides; diagnosis |
| 03/27/2001 | US6207802 Non-human, mammalian polypeptide of defined amino acid sequence which activates the growth of early hematopoietic progenitor cells; treatment of blood disorders; anticarcinogenic agents; bone marrow regeneration |
| 03/27/2001 | US6207697 Amidinyl-substituted rings; anticoagulants; thromboembolic disorders; antiischemic and antiinflammatory agents; strokes; serine protease inhibitors |
| 03/27/2001 | US6207693 Benzamide derivatives having a vasopressin antagonistic activity |
| 03/27/2001 | US6207453 A replication-defective adeno-associated virus vector containing exogenous dna bound to a dna which codes for a rep protein; gene therapy |
| 03/27/2001 | US6207417 DNA encoding stem cell factor |
| 03/27/2001 | US6207195 Sodium 4-phenylbutyrate in solid nanosphere formed by coacervation of a polycation, i.e., a protein and a polyanion, i.e., a nucleic acid; treatment of cystic fibrosis |
| 03/27/2001 | CA2166297C Process for manufacture of 1-deamino-8-d-arginine vasopressin |